Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...
SAN FRANCISCO -- Another COVID-19 vaccine -- AstraZeneca -- is poised to arrive in the U.S., bringing a fourth option for Americans. Each vaccine is administered slightly differently, some can result ...
Pfizer ended its six-month effort to buy AstraZeneca Monday following the London-based company's May 19 rejection of its last bid of 55 pounds a share in cash and stock. While British takeover law ...
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I'm back in ...
A pre-clinical study published in The Lancet on June 25 found that mixing AstraZeneca with a second dose of Pfizer provides "robust" protection from severe COVID-19. The pre-clinical study was ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. CHICAGO — Funding cancer research isn't usually a ...
Hosted on MSN
We wanted to help end the world's biggest disruption. But no one considered the consequences
Multiple people across the globe who stepped forward early to receive the Covid vaccine are speaking about what they say is the debilitating neurological condition they developed after getting the ...
A new Reuters report, based on data from healthcare research firm 3 Axis Advisors, names Pfizer (PFE) and GSK (GSK) among the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback